Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Payables (2016 - 2026)

Perspective Therapeutics' Payables history spans 16 years, with the latest figure at $26.5 million for Q1 2026.

  • On a quarterly basis, Payables rose 202.05% to $26.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $26.5 million, a 202.05% increase, with the full-year FY2025 number at $20.6 million, up 97.85% from a year prior.
  • Payables hit $26.5 million in Q1 2026 for Perspective Therapeutics, up from $20.6 million in the prior quarter.
  • Over the last five years, Payables for CATX hit a ceiling of $26.5 million in Q1 2026 and a floor of $150000.0 in Q2 2022.
  • Historically, Payables has averaged $8.1 million across 5 years, with a median of $6.7 million in 2023.
  • Biggest five-year swings in Payables: tumbled 73.83% in 2022 and later skyrocketed 4352.0% in 2023.
  • Tracing CATX's Payables over 5 years: stood at $233000.0 in 2022, then soared by 2886.27% to $7.0 million in 2023, then skyrocketed by 49.4% to $10.4 million in 2024, then surged by 97.85% to $20.6 million in 2025, then grew by 29.05% to $26.5 million in 2026.
  • Business Quant data shows Payables for CATX at $26.5 million in Q1 2026, $20.6 million in Q4 2025, and $13.2 million in Q3 2025.